Group 1 - The core point of the article is the announcement by the company regarding the resignation of its executive director and the appointment of a new authorized representative [1] Group 2 - Pan Weidong will resign as the company's executive director effective from November 4, 2025, due to personal matters [1] - Li Chunlei has been appointed as the new authorized representative of the company [1]

Core Points - The company announced that Mr. Pan Weidong will resign as an executive director effective from November 4, 2025, due to personal matters [1] - Dr. Li Chunlei has been appointed as the authorized representative of the company [1]

Group 1 - The core point of the article is the resignation of Mr. Pan Weidong as an executive director of the company, effective from November 4, 2025, due to personal matters [1] - Dr. Li Chunlei has been appointed as the authorized representative of the company following Mr. Pan's resignation [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 石藥集團有限公司（「本公司」）董事會（「董事會」）宣佈，自2025年11月4日起生效： (1) 潘衛東先生（「潘先生」）因需要更多時間處理其個人事務而辭任本公司執行董事及不再 根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則 第 3.05 條 擔 任 本 公 司 的 授 權 代 表（「授 權 代 表」）； (2) 本公司執行董事李春雷博士獲委任為授權代表。 潘先生已確認彼與董事會並無意見分歧，且除已公開披露的信息外，並不知悉任何與其辭 任有關而需本公司股東關注的事項。 （股份代號：1093） （於香港註冊成立之有限公司） 執行董事辭任 及更換授權代表 承董事會命 石藥集團有限公司 主席 蔡東晨 香港，2025年11月4日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 ...

Core Points - The China Securities Regulatory Commission (CSRC) imposed a fine of 5 million RMB on Pan Weidong, an executive director of CSPC Pharmaceutical Group, for insider trading [2] - Pan Weidong's insider trading involved purchasing shares of New Horizon (a subsidiary of CSPC) prior to a planned acquisition announcement [2] - The acquisition plan was announced on January 10, 2024, while the stock purchases occurred between December 8 and December 20, 2023, totaling nearly 100 million RMB [2] - The stock purchases did not yield profits, as the current stock price of New Horizon is below the purchase price [2] - CSPC stated that the incident is not expected to negatively impact its overall business operations [4] Regulatory Actions - Pan Weidong contested the allegations, claiming that his actions were part of his official duties and that he did not evade the investigation [3] - The CSRC's administrative penalty was publicly announced on October 16, 2025, with CSPC disclosing the matter shortly after [3] - Other individuals involved in the case, including former executives of New Horizon and CSPC, received penalties for their trading activities, with some gaining profits from their transactions [5] Market Reaction - Following the announcement of the penalties, both CSPC and New Horizon experienced declines in their stock prices, with CSPC dropping 4.42% to 7.35 HKD per share and New Horizon falling 5.29% to 33.32 CNY per share [5]

Core Viewpoint - The article discusses the termination of a significant asset restructuring and related party transaction by XinNuoWei, which was valued at 7.6 billion yuan, and the subsequent insider trading penalties imposed on its former chairman, Pan Weidong [1][8]. Group 1: Insider Trading and Penalties - Pan Weidong, the former chairman of XinNuoWei, was fined 5 million yuan for insider trading related to the company's planned acquisition of Shiyao Baike [3][7]. - The China Securities Regulatory Commission (CSRC) found that Pan purchased 2.7426 million shares of XinNuoWei for nearly 100 million yuan between December 8 and 20, 2023, after being aware of insider information [3][5]. - Other individuals, including Zhang Heming, Du Ying, and Zhen Hong, also received penalties for their involvement in insider trading, with fines and confiscation of illegal gains totaling 150,000 to 238.41 million yuan [5][6]. Group 2: Termination of Restructuring - XinNuoWei announced the termination of its 7.6 billion yuan acquisition of Shiyao Baike due to changes in the pharmaceutical industry and capital market conditions since the restructuring was first planned [12]. - The acquisition was intended to enhance XinNuoWei's biopharmaceutical portfolio, particularly in long-acting proteins and innovative drug pipelines [9][12]. - The restructuring was initially planned to involve a 90% share issuance and 10% cash payment for the acquisition of 100% equity in Shiyao Baike [8][9]. Group 3: Financial Performance - XinNuoWei's financial performance showed a decline, with revenues of 1.981 billion yuan in 2024 and 1.593 billion yuan in the first nine months of 2025, reflecting year-on-year decreases of 21.98% and an increase of 7.71%, respectively [13]. - The net profit for XinNuoWei was reported at -303 million yuan in 2024 and -310 million yuan in the first nine months of 2025, indicating significant losses [13].

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling 0.79% to 25,952.4 points, and the Hang Seng Technology Index dropping 1.76% to 5,818.29 points, amid a total trading volume of HKD 239.99 billion [1] - Dongwu Securities indicated that the Hong Kong market is entering an adjustment phase towards the end of the year, although it remains in a medium to long-term upward trend [1] Blue-Chip Stocks Performance - Baidu Group (09888) rose 2.87% to HKD 121.9, contributing 6.83 points to the Hang Seng Index, with weekly orders for its service exceeding 250,000 [2] - Other notable blue-chip movements included Kang Shifu Holdings (00322) up 3.27%, and China Merchants Bank (03968) up 2.37%, while Zijin Mining (02899) fell 5.36% [2] Sector Performance - The technology sector saw most large-cap stocks decline, with Alibaba down 2.57% and Tencent slightly up by 0.16%, while Baidu gained nearly 3% [3] - The cryptocurrency sector faced significant pressure, with major declines in related stocks, and Bitcoin prices dropping below USD 105,000 [4] - Apple-related stocks generally fell, with notable declines in companies like Q Technology (01478) and BYD Electronics (00285) [4][5] Lithium Sector - Lithium stocks continued to decline, with Ganfeng Lithium (01772) down 5.85% and Tianqi Lithium (09696) down 4.68% [6] - The price of lithium carbonate futures fell over 4%, with market speculation surrounding the production timeline of CATL's projects [7] Notable Stock Movements - Aide New Energy (02623) surged 290% after announcing a major share sale [8] - Yum China (09987) rose 3.83% ahead of its upcoming financial results [8] - Sanhua Intelligent Controls (02050) fell 6.4% after a downgrade by Goldman Sachs, citing overly optimistic market expectations for its humanoid robot business [9]

Core Points - The executive director of CSPC Pharmaceutical Group, Pan Weidong, was fined 5 million RMB for insider trading related to a failed acquisition deal [1][2] - The insider trading incident involved the purchase of shares in CSPC Innovation Pharmaceutical Co., which was led by Pan Weidong prior to the public announcement of the acquisition [1][2] Summary by Sections Insider Trading Incident - Pan Weidong was found to have knowledge of insider information regarding a restructuring transaction before it was made public, specifically before December 5, 2023 [1][2] - He used the securities account of CSPC's subsidiary, Enbipu, to buy 2.74258 million shares of CSPC Innovation from December 8 to December 20, 2023, totaling approximately 99.99 million RMB [1] Regulatory Actions - The China Securities Regulatory Commission (CSRC) deemed Pan Weidong's actions as insider trading and imposed a fine of 5 million RMB [2] - Pan Weidong has the right to apply for administrative reconsideration or file an administrative lawsuit against the CSRC's decision [2] Impact on Company Operations - The restructuring transaction that Pan Weidong was involved in has been terminated and was not completed as of April 2025 [2] - CSPC Pharmaceutical Group stated that its business operations remain normal and that the penalty is not expected to negatively impact the overall business [2]

Policy Developments - The National Health Commission and five other departments launched a one-year special campaign against illegal ambulances, targeting both registered "ambulance" vehicles and unregistered "black ambulances" [2] - The campaign includes comprehensive inspections, management principles, and encourages social participation in medical transport services [2][3] Drug and Medical Device Approvals - Aied Bio received a medical device registration certificate for its gene mutation detection kit, which is now approved in China, Japan, and Europe, aiding non-small cell lung cancer patients [4] - Hainan Haiyao's subsidiary obtained a drug registration certificate for Fumaric Acid Vonoprazan Tablets, the first P-CAB for reflux esophagitis in China [5] Capital Market Activities - China National Pharmaceutical Modern signed a drug listing license transfer contract for Lactulose Oral Solution, with a total transfer fee of 5.86 million yuan, projected to generate 2.069 billion yuan in sales in 2024 [6] - Jiangsu Hengrui Medicine and Neurocrine Biosciences entered a collaboration for developing NLRP3 inhibitors, with a potential total value of $881.5 million [7][8] Industry Events - The 2025 medical insurance negotiation concluded, with results expected to be announced in early December [9] - The only approved stem cell drug in China, Aimi Maito Sai Injection, is included in the "Beijing Universal Health Insurance" with a maximum reimbursement of 65% [10] Regulatory Issues - The executive director of CSPC Pharmaceutical Group was fined 5 million yuan for insider trading related to a merger announcement [11]

Core Viewpoint - The executive director of CSPC Pharmaceutical Group, Pan Weidong, has been fined 5 million yuan for insider trading related to a subsidiary's restructuring transaction [1][3]. Group 1: Insider Trading Incident - The incident traces back to December 8, 2023, when CSPC's indirect subsidiary, CSPC Innovation, announced that its largest shareholder, Enbipu, planned to increase its stake in CSPC Innovation by up to 100 million yuan within six months [2]. - Pan Weidong, who was the chairman of CSPC Innovation at the time, was aware of insider information regarding a restructuring transaction before it was made public [2]. - Between December 8 and December 20, 2023, Pan utilized Enbipu's securities account to purchase 2.7426 million shares of CSPC Innovation, totaling approximately 99.9888 million yuan [2]. Group 2: Regulatory Actions - The China Securities Regulatory Commission (CSRC) determined that Pan's actions constituted insider trading and mandated him to handle the illegal securities holdings, imposing a fine of 5 million yuan [3]. - CSPC Pharmaceutical Group stated that the penalty is not expected to negatively impact the overall business operations of the company [4]. Group 3: Company Background and Financial Performance - CSPC Innovation, established in 2006 and previously known as CSPC New Drug Co., Ltd., went public on the Shenzhen Stock Exchange in 2019 [4]. - For the first three quarters of 2025, CSPC Innovation reported a revenue of 1.593 billion yuan, reflecting a year-on-year increase of 7.71%, while the net profit attributable to shareholders was a loss of 24.0489 million yuan, a decline of 117.26% year-on-year [5].